Cinaciguat Hydrochloride is a soluble guanylate cyclase (sGC) activator used as an investigational treatment for acute decompensated heart failure by enhancing nitric oxide signaling and improving cardiac… Read more
Cinaciguat Hydrochloride is a soluble guanylate cyclase (sGC) activator used as an investigational treatment for acute decompensated heart failure by enhancing nitric oxide signaling and improving cardiac output. This distinct class of compounds functions as a direct sGC stimulator, differing from traditional phosphodiesterase inhibitors in its mechanism of action. To support rigorous pharmaceutical analysis, this category provides high-quality reference standards of the active pharmaceutical ingredient, alongside its related impurities, metabolites, and stable isotope-labelled compounds. These materials are essential for laboratories conducting impurity profiling, method development, and validation during the quality control process. By utilizing these precisely characterized reference standards and isotope-labelled internal standards, researchers can ensure accurate quantification and regulatory compliance in their analytical testing protocols for this potent cardiovascular therapy.